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High-grade gliomas (HGGs) are aggressive primary brain tumorswith local invasive growth and poor clinical prognosis in
both adult and pediatric patients. Clinical response is compounded by resistance to standard frontline antineoplastic
agents, an absence of novel therapeutics, and poor in vitro models to evaluate these. We screened a range of recently
identifiedanticancer compounds inconventional adult, pediatric, andnewbiopsy-derivedHGGmodels. These in vitro lines
showed a range of sensitivity to standard chemotherapeutics, with varying expression levels of the prognostic markers
hypoxia-induced factor (HIF) 1a and p53. Our evaluation of lead DIVERSet library compounds identified that JAG-6A, a
compound thatwassignificantlymorepotent than temozolomideoretoposide,waseffectiveagainstHGGmodels in two-
dimensional and three-dimensional systems; mediated this response by the potent inhibition of topoisomerase Iia;
remained effective under normoxic and hypoxic conditions; and displayed limited toxicity to non-neoplastic astrocytes.
These data suggest that JAG-6A could be an alternative topoisomerase IIa inhibitor and used for the treatment of HGG.
Translational Oncology (2019) 12, 1375–1385© 2019 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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In 2015 alone, 22,850 adults (12,630 men and 10,280 women) were
In silico analysis using the DIVERSet compound library fromdiagnosed with brain and other central nervous system (CNS) cancers in
theUnitedStates,with 15,320 resulting in patient death [1].High-grade
gliomas (HGGs) account for 52% of all primary brain tumors and in
children occur at a frequency of 5.7 cases per 100,000 [2]. Adult HGG
(aHGG) treatment comprises a multidisciplinary approach including
surgical resection and combined radio- and chemotherapy [3]. Despite
this, mean patient survival is less than 15months [4,5]. The current
standard chemotherapeutic for aHGG treatment is the DNA alkylating
drug temozolomide (Temodal) (TMZ) [6,7]. The addition of TMZ to
the surgical and radiotherapy regimen (the “Stupp protocol”) demon-
strated a significant patient survival benefit with a median increase in
survival of 2.5 months [8]. However, this protocol yields a 24-month
progression-free survival of just 14%,where a discernible TMZ response
was only noted in tumors exhibiting O6-methylguanine DNA
methyltransferase (MGMT) promoter methylation [9]. Irrespective of
MGMT promoter methylation, almost all patients demonstrate disease
relapse and eventual progressive disease. Pediatric HGG (pHGG) is
significantly different from adult disease, where recent substantive
genomic and epigenomic studies has resulted in an almost complete
reclassification of childhood brain tumors, incorporating diverse
histological and molecular-phenotype differences [10e12]. Both adult
and pediatric HGGs present with areas of attenuated vascularization
forming hypoxic regions (areas of insufficient oxygenation) [13e15].
This environment drives the modulation and stabilization of hypoxia
induced factor (HIF)-1a, a transcription factor implicated in oncogen-
esis, angiogenesis, proliferation, and invasion. HIF-1a expression
correlates with poor clinical prognosis, in part due to co-inhibition of
the p53 mediated proapoptotic network in HGG [16,17]. While TP53
mutations have not been associated with aHGG patient prognosis,
approximately 40%of pHGGs are associatedwithTP53mutations [18]
[12], and this correlated with patient prognosis [19e21].
Similar to aHGG patients, pHGG treatment consists of an
aggressive multidisciplinary approach that incorporates surgery (if
possible), radiotherapy, and chemotherapy [22]. Prognosis remains
dismal with 5-year progression-free survival between 10% and 30%
[23e26]. In contrast to aHGG where TMZ treatment has a clear
therapeutic benefit, within the pHGG patient population, TMZ
regimens revealed no impact on patient outcome [27,28]. Conse-
quently, pHGG chemotherapy regimens incorporate procarbazine,
lomustine, etoposide, cisplatin, and vincristine [3,27,29e31]. The
incorporation of etoposide (in combination with cisplatin) represents
a common treatment modality for patients and is a compelling
therapeutic agent. Etoposide, a topoisomerase II poison, induces
double-strand DNA breaks by increasing the amount of cleavable
topoisomerase II:DNA complexes. The level of these complexes is
topoisomerase II concentration dependent, where it is far higher in
rapidly dividing cancer cells versus non-neoplastic cells [32].
Topoisomerase II inhibitors have been extensively tested against a
number of cancer types and have shown promise against aHGG
[33,34]. One of the critical limitations for topoisomerase II poisons
relates to their pharmacokinetic profile and poor bloodebrain barrier
permissiveness. Despite these limitations, there have been a number
of approaches to enhance the delivery of these agents into the CNS.
This includes convection enhanced delivery [35]. Importantly, the
identification of novel therapeutics, particularly topoisomerase II
poisons with a significantly lower molecular weight (with increase
solubility), would be of significant interest to the field.Chembridge (San Diego, CA) identified a number of lead anticancer
agents for further analysis [36]. Here we performed in vitro
two-dimensional (2D) and three-dimensional (3D) analysis of
conventional and recently obtained, biopsy-derived aHGG cells as
well as established pHGG cells following exposure to each lead agent.
We evaluated cell viability posttreatment with each compound and
evaluated the effect of these compared to TMZ, etoposide,
vincristine, and gemcitabine. We revealed that the lead agents were
potent inhibitors of topoisomerase II and, consistent with this cellular
target, examined the HIF-1a and p53 signaling networks in key
HGG lines following exposure to these compounds.
Methods and Methods
Tumor Specimens and Primary Tumor Cultures
Following informed consent and in accordance with the LREC
review board (11/SC/0048), HGG samples were obtained from
patients undergoing biopsy surgery at Kings College Hospital NHS
Foundation Trust (London, UK).Tumors were classified based on
WHO criteria after examination by neuropathologists. The tumor
mass was mechanically dissociated into explant clumps, allowing
neoplastic cells to colonize the flask. Biopsies were cultured in
DMEM with 10% heat-inactivated FCS. Upon establishment of cell
cultures, a combined STR profile was conducted for each adult HGG
(Agilent Bioscience). All experimental protocols were approved by the
University of Portsmouth, Faculty of Research.
Chemotherapeutics and Cell Culture
TMZ (T2577) and vincristine (V0400000) were from Sigma-Al-
drich. Gemcitabine (S1714) was from SelleckChem. JAG-6A, CC-I,
JAG-32, and JAG-79 were provided by Opal Oncology (Cambridge,
UK). U87MG was obtained from the ATCC. KNS42 and SF188
cells were obtained from Professor Chris Jones (Institute of Cancer
Research, London, UK). UP-029, SEBTA-003, SEBTA-023, and
SEBTA-025 were cultured in DMEM (61965 Fisher Scientific)
supplemented with 10% HIFBS (F7524-500ML Sigma-Alrich).
SC1800 and CC2565 non-neoplastic astrocytes were purchased from
Lonza and maintained in astrocyte growth medium supplemented
with SingleQuots (CC-3187 Lonza) including (CC-4123) rhEGF,
insulin, ascorbic acid, and L-glutamine. Cells were cultured under
normoxic (21%) or hypoxic (1%) O2.
Spheroid Formation and Staining Assay
We modified the Sirenko and Montenegro et al. protocol [37,38].
Cells were seeded in ultra-low adherence plates and treated with
compounds after 12 hours. Spheroids were stained in 4 mM Calcein
AM (Fisher Scientific, C1430), 50 mg/ml propidium iodide (PI)
(Fisher Scientific, P3566), and 33 mM Hoechst 33342 (Fisher
Scientific, H1399) in phenol-free, serum-free DMEM. Imaging was
conducted on InCell 6000 at 10 magnification, 4 fields with 15%
overlap, 13 z-stacks, and 20 mM per step. Z-stacks were compressed
with maximum projection, extended focus algorithm, to a single
in-focus image. Four fields were stitched to a single image. Each
individual stained image is included in Supplemental Figure 1.
MTS Cell Viability Assay
Cells were seeded in triplicate in a 96-well plate. Twenty--
four hours postseeding, cell lines were treated at varying dosages of
each therapeutic agent. MTS assay (G3580 Promega) was conducted
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Absorbance at 490 nm was recorded on BMG Labtech Polarstar.
Annexin V/propidium Iodide Apoptosis Assay
Cells after the treatment with each agent were collected, and the
cell concentration was determined using a Countess II FL (Thermo
Fisher, UK). Cells were centrifuged at 400g for 5 minutes, and the
pellet was resuspended in 300 ml PBS. Cells were centrifuged again at
400g for 5 minutes, and the pellet was resuspended in 100 ml Annexin
V binding buffer. Annexin V-CF488A conjugate was added to the
cells including Hoechst (final concentration: 10 mg/ml) and mixed by
pipetting. Cells were incubated at 37C for 15 minutes. Following
incubation, cells were centrifuged at 400g for 5 minutes. The cell
pellet was resuspended in Annexin V binding buffer and centrifuged
again, and the pellet was resuspended in Annexin V supplemented
with 10 mg/ml PI. Samples were run and analyzed using a
NucleoCounter NC-3000 (Chemometec, Denmark).
Western Blot Analysis
Total protein was harvested using RIPA buffer (89900, Thermo--
Fisher) and 1 protease inhibitor cocktail (78442 Thermo-Fisher).
Primary antibodies HIF-1a (ABE279 Millipore), p53 (DO1, sc-126
SCBT), or b-actin (sc-47778 SCBT) were added to the membrane
overnight. Secondary antibody was added (LICOR) at 1:10,000
dilution for 1 hour. Membranes were imaged on Odyssey CLX
(Licor). All full-length gels and blots are included in our Supple-
mental Information file (Supplemental Figures 2-4).
Quantitative Real-Time PCR
Total RNA was extracted (RNAeasy, 74104 Qiagen) and
quantified using RNA6000 chip arrays (Agilent Bioscience).
Real-time PCR was performed per sample in triplicate on a Roche
LightCycler 96. Primers are as follows: PUMA (fwd 5-gacctcaacgca-
cagtacga-3 and rev 5-tgggtaagggcaggagtc-3), Bax (fwd 5-ctgacgg-
caacttcaactg-3, rev 5-cactgtgacctgctccagaa-3). p21 (fwd
5-ggaagaccatgtggacctgt-3, rev 5-aagatgtagagcgggccttt-3). Aldolase c,
(fwd 5-tctctcaacctcaat-3, rev 5-agtacatagc-3). HEK2 (fwd
5-tcgcatctgcttgcctacttc-3, rev 5-cttctggagcccattgtccgt-3), and
GAPDH (fwd 5-gagtcaacggatttggtcgt-3, rev 5-ttgattttggagggatctcg-3).
Data analysis was carried out using the 2ΔΔCT method [39].
Topoisomerase IIa Decatenation Assay
Kinetoplast DNA (kDNA) decatenation assay was performed using
a Topopoisomerase II assay kit (TopoGEN, Inc., Port Orange, FL)
according to the manufacturer’s instructions. Topoisomerase IIa
decatenates kDNA which consists of highly catenated networks of
circular DNA in an ATP-dependent reaction to yield individual
minicircles of DNA. In brief, for topoisomerase IIaemediated kDNA
decatenation assay, the 20-ml reaction mixture contains the following
components: 50 mM TriseHCl, pH 8.0, 150 mM NaCl, 10 mM
MgCl2, 0.5 mM dithiothreitol, 30 mg/ml bovine serum albumin,
2 mM ATP, 260 ng of kDNA, several concentrations of compounds,
and 4 U of human topoisomerase IIa. The final concentration of
0.5% (v/v) DMSO was used.
Molecular Modeling Study
The molecular modeling studies were based on the X-ray crystal
structure of human topoisomerase IIa (5BTD). Calculations were
performed using the program Molecular Operating Environment(Chemical Computing Group Inc., Montreal, Canada). Ligand
binding energies in kcal/mol were calculated using force field
refinement (Amber12EHT) following initial placement via the
“Triangle Matcher” placement methodology.
Scanning Electron Microscopy
Spheroids were fixed with 2.5% glutaraldehyde and 2%
paraformaldehyde in phosphate buffer (0.1 M, pH 7.4) and treated
with 1.5% potassium ferrocyanide and 1% osmium tetroxide, then
with 1% osmium tetroxide and a final 1% aqueous uranyl acetate.
Spheroids were imaged at 80 kV on Zeiss EVO MA10 SEM.
Data Analysis and Statistics
In vitro experiments were analyzed (GraphPad Prism) and are
represented as mean values ± SD, indicating the number of
experiments carried out for each assay. Statistical significance has
been calculated using Student’s t test, (*P .05), two-tailed ANOVA
analysis, or the log-rank test for Kaplan-Meier survival analyses.
Results
Conventional Chemotherapeutics Significantly Reduce aHGG
Cell ViabilityWe obtained aHGG-derived biopsy material and isolated in vitro cell
lines designated UP-029, SEBTA-023, SEBTA-025, and SEBTA-003.
Each was DNA fingerprinted using a combined short tandem repeat
and fragment-length amplification [40]. We included the human
glioma cell line U87MG in our studies. While the U87MG model has
been questioned, U87MG is HGG in origin and is a widely used in
vitro model for preclinical testing [41,42]. U87MG cells were exposed
to TMZ, gemcitabine, etoposide, or vincristine for 96 hours under
normoxic conditions (Figure 1A). U87MG cells were refractory to
TMZ (EC50¼ 15.8 mM), gemcitabine (EC50¼ 103.6 mM), and
etoposide (76.4 mM), although they were sensitive to vincristine
(EC50¼ 0.315 nM). We questioned if any of our biopsy-derived
aHGG cell lines were sensitive to these standard frontline chemother-
apeutics (Figure 1, B-E). The most potent chemotherapeutic tested was
vincristine. The UP-029 aHGG cells displayed sensitivity to TMZ
(Figure 1B), whereas both SEBTA-025 (Figure 1C) and SEBTA-003
(Figure 1D) aHGG cell lines were refractory to this chemotherapeutic.
In contrast, the SEBTA-023 aHGG cells were highly resistant to all
chemotherapeutics except vincristine (Figure 1E).
Novel Anticancer Agents Mediate a Potent Cytotoxic Response
in Adult HGG
We next questioned if any of our lead DIVERSet anticancer agents
[termed JAG-6A, CC-I (JAG-31), JAG-32, and JAG-79] (Figure 2A)
would demonstrate an anti-HGG effect in the U87MG model
(Figure 2B) or in our novel biopsy lines (Figure 2, C-F). The U87MG
cells showed sensitivity to the JAG agents, in particular JAG-6A (EC50
3.6 mM) and CC-I (EC50 7.4 mM). Similarly, JAG-6A was the most
potent therapeutic in our novel in vitromodels. We next compared the
average EC50 value at 96 hours posttreatment following the single
exposure of each cell line to TMZ, etoposide, or JAG-agent (Figure 2G).
For each in vitro cell line, JAG-6A was significantly more effective than
TMZ or etoposide. The biopsy-derived HGG cell lines were
significantly more resistant to these fronttline chemotherapeutics
when compared to the widely utilized U87MG cell line. The
SEBTA-023 aHGGmodel was highly resistant to all compounds tested.
Figure 1. Novel biopsy-derived aHGG cell lines display varying sensitivity to the chemotherapeutics temozolomide, gemcitabine,
and vincristine. (A) U87MG, (B) UP-029, (C) SEBTA-025, (D) SEBTA-003, and (E) SEBTA-023 were seeded in 96-well plates overnight.
The next day, cells were treated with temozolomide (128mM), gemcitabine (330mM), or vincristine (1mM) in DMEM.
Ninety-six hours posttreatment, loss of cell viability was assessed by CellTiter 96 AQueous One Solution Cell Proliferation Assay
(Promega). Data presented as mean average of n¼ 3 ± SD.
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(Figure 2H). Twenty-four hours following JAG-6A treatment, each
biopsy-derived aHGG cell line displayed morphology changes,
including rounding up, membrane blebbing, and monolayer detach-
ment (Figure 2H panel 3). This phenotype was not as pronounced
24 hours posttreatment with CC-I or JAG-79 (Figure 2H panel 4 and
6). No cell morphology changes were noted following JAG-32
exposure (Figure 2H panel 5). Consistent with our viability studies,
some rounding up, membrane detachment, and cell death were notedpost-TMZ exposure. We questioned the mechanism of cell death
following exposure to each JAG agent. Our aHGG lines were treated
with TMZ or each JAG agent up to 96 hours. Annexin V/PI staining
was conducted, and in agreement with our previous data, we noted a
significant increase in Annexin V and Annexin V/PI staining
posttreatment with each compound (Figure 2I). For each in vitro
model, Annexin V and dual Annexin V/PI staining was highest
following JAG-6A treatment. TMZ, CC-I, and JAG-32 exposure each
induced limited Annexin V and Annexin V/PI staining.
Figure 2. Novel JAG anticancer agents demonstrate a differential and significant anti-aHGG response. (A) Chemical structure of
each JAG agent used in this study. (B) U87MG cells (5103 per well) were seeded overnight and treated the following day with
JAG-6A (black), CC-I (blue), JAG-32 (green), or JAG-79 (purple) at1000 μM. Ninety-six hours posttreatment, loss of cell viability was
assessed by CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega). Data presented as average of n¼ 3
independent studies ± SD. (C-F) JAG agent susceptibility was determined for each novel aHGG model. (G) Average EC50 values
(±SD) for TMZ and each JAG agent were determined. Two-tailed ANOVAs was conducted, and P values are shown for each
comparison; n¼ 3. (H) Representative microscopy (10) images of UP-029 cells. UP-029 aHGG cells were seeded (1104). The
next day, cells were treated with indicated agents (10mM TMZ or 30 μM per JAG agent) and imaged (up to 24 hours) at 37C under
normoxic conditions. Images were recorded using EVOS FL Auto (Life Technologies). (I) Apoptosis assays were conducted for each
indicated cell line 24 hours post 30 μM treatment with each JAG agent. Annexin V/PI staining was conducted and apoptosis status
was determined using an NC-3000 counter; n¼ 3± SD.
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In Vitro Models
Having observed that some JAG agents were effective in various
aHGG models, we questioned if these agents were effective against
pHGG. KNS42 or SF188 (both grade IV) cells were treated with JAG
agents (Figure 3, A-B). Similar to our aHGG cells, KNS42 cells
displayed varying sensitivity post-JAG agent treatment, with JAG-6A
being the most potent compound tested. SF188 cells showed notable
resistance to these therapeutics, exhibiting sensitivity at only the very
highest tested drug concentrations. We observed that pHGG cell
morphology changed following JAG agent exposure consistent with
cell viability (Figure 3,C andD). JAG-6A induced themost prominentchange in KNS42 cell morphology 24 hours posttreatment, character-
ized by extensive rounding up and monolayer detachment. We
conducted Annexin V/PI staining in our pHGG cells following
treatment with each JAG-agent (Figure 3D). We noted that, 24 hours
posttreatment, there was a significant increase in both early and late
apoptotic cell populations. As we would predict from our previous
data, limited apoptosis was detected in JAG agentetreated SF188 cells.JAG Anticancer Agents Are Well Tolerated by Non-Neoplastic
Astrocytes
A critical consideration for any therapeutic is toxicity to
non-neoplastic cells. We questioned the sensitivity of the
Figure 3. JAGagentsmediate a potent anti-pHGG responsewith limited toxicity to non-neoplastic astrocytes. (A) KNS42and (B) SF188
pHGGcells treatedwith each JAGagent. After 96 hours, loss of cell viabilitywas determinedbyCellTiter 96AQueousOne SolutionCell
ProliferationAssay (Promega).Representativemicroscopy (10) imagesof (C)KNS42andSF188cells.Cellswere treatedwith indicated
agents (30 μMper JAG agent) and imaged (up to 24 hours) at 37C under normoxic conditions. Images and films were recorded using
EVOSFLAuto (Life Technologies). (D) Apoptosis assayswereconducted for each indicated cell line24 hourspost 30 μMtreatmentwith
each JAGagent. Annexin V/PI stainingwas conducted, and apoptosis statuswas determinedusing anNC-3000 counter; n¼ 3± SD. (E
and F)Dose-response curves for non-neoplastic CC2565cells following exposure to TMZ (128mM), vincristine (1mM), or individual
JAG agents1000 μM in complete astrocyte growth medium. Data presented as average of n¼ 3. Error bars indicate ±SD.
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therapeutic (Figure 3E) and JAG agent (Figure 3F). TMZ and JAG
agents were well tolerated; however, CC2565 cells displayed
significant sensitivity to vincristine.
JAG Anticancer Agents Remain Effective Under Hypoxic
Conditions
In addition to non-neoplastic cell tolerance, any HGG therapeutic
must remain effective under hypoxic (1%) O2 conditions. To address
this question, we examined cell viability posttreatment under both
normoxic (21%) and hypoxic (1%) O2 conditions. Taking this into
consideration, we determined that there was no significant difference
in EC50 value for each JAG agent under hypoxic conditions. Both
JAG-6A and CC-I remained effective under this condition (Figure 4,
A-B). Supporting our previous data, SF188 cells showed little to no
response to each JAG agent irrespective of oxygenation levels
(Figure 4C). For each of our tested cell lines, there was no statistical
difference between EC50 values for any of the tested agents under
either hypoxic or normoxic conditions.
Differential Prognostic Protein Expression Occurs in Adult and
Pediatric HGG Models
Based on these hypoxia studies, we next assessed HIF-1a protein
expression under both normoxic and hypoxic conditions (Figure 4D).
Under normoxic conditions, UP-029, SEBTA-023, and SEBTA-003
aHGG cells demonstrated high HIF-1a protein expression. KNS42
and SF188 pHGG cells also had detectable HIF-1a protein
expression under normoxic conditions, a characteristic indicative of
poor clinical prognosis (Figure 4E). Non-neoplastic CC2565 cells
showed little HIF-1a protein expression under normoxic conditions,
although after hypoxic incubation, they showed protein accumulation
(Figure 4F). We questioned if this accumulation correlated with
HIF-1aedependent gene transcription. Consistent with our HIF-1a
data, there was expression of aldolase c and HEK2 under normoxicand hypoxic conditions in HGG (Figure 4G). In contrast to aHGG
cells, a significant increase in aldolase c and HEK2 transcription in
non-neoplastic astrocytes was observed after hypoxic incubation.
Under normoxic conditions, there was significant variation in the
total p53 protein level in our cell lines (Figure 4, D and E). There was
detectable total p53 in the UP-029 cells, while the SEBTA-023 cell
line had little to no detectable total p53. SF188 cells showed an
appreciably lower, albeit specific, band. We questioned if our HGGs
demonstrate p53 accumulation and/or activation posttreatment with
each JAG agent or TMZ (Figure 4H). We observed the accumulation
of total p53 after JAG-6A, CC-I, or JAG-32 exposure in the UP-029
aHGG cells. Both SEBTA-023 and SF188 showed no detectable total
p53 and suggest, with our previous data, that there was a p53
dependency for these anticancer agents. We questioned if there were
any changes in p53-dependent gene expression, in particular, those
that direct apoptosis or cell cycle arrest (Figure 4I).
We found that there was little to no induction of p21 transcription
but significant expression of PUMA and Bax consistent with the
apoptosis and cell death previously described. Similarly, we detected
PUMA and Bax transcription following TMZ or etoposide exposure
(Figure 4J).
JAG-6A Mediates a Potent Cytotoxic Response in Adult and
Pediatric HGG 3-D Spheroids
Having revealed a strong anti-aHGG response post-JAG-6A
treatment, we questioned if the effectiveness of this compound
when used to treat 2D cell cultures was conserved in 3D models. We
established two 3D HGG spheroid models: one adult, (UP-029) and
one pediatric (KNS42). Both formed robust spheroids, observed by
confocal (Figure 5A) and scanning electron microscopy (Figure 5B).
Spheroids were established and, 12 hours postdevelopment, exposed
to JAG agents or TMZ (Figure 5C). The percentage of live cells in
mock treated KNS42 and UP-029 spheroids remained high (87%
±5.26% and 96.0% ±1.957%) up to 72 hours (Figure 5D). A
Figure 4. JAG agents are effective under hypoxic conditions, while novel aHGG models express differential levels of HIF1a and p53.
Average EC50 values (±SD) at 96 hours posttreatment for TMZ and each JAG agent were determined under normoxic (21% O2) or
hypoxic (1%O2) conditions. (A) UP-029 aHGG, (B) KNS42, and (C) SF188 pHGGcells; n¼ 3. Two-tailedANOVAwas conducted for each
pair; all comparisonswere not significant. (D) Novel aHGG cells, (E) pHGG cells, and (F) non-neoplastic astrocyteswere cultured under
normoxic (NT) or hypoxic (1% O2) conditions for up to 72 hours, and total protein lysates were analyzed by Western blotting. (G)
Indicated cell lineswereculturedundereither normoxic (21%O2) or hypoxic (1%O2) conditions for 24 hours. Cellswere collected at the
end of the incubation. RNA was extracted and qRT-PCR for aldolase c and HEK2mRNA was analyzed; n¼ 3. Shown are fold change in
aldolase corHEK2 relative toGAPDH. (H) (left)UP-029aHGGcellswereculturedundernormoxicconditionsandexposed to10 μMJAG-6A,
CC-I, JAG-32, or TMZ up to 24 hours. (Middle) UP-029 cells were treatedwith 10 μMJAG-6A or TMZ up to 24 hours. (Right) KNS42 cells
were treatedwith10 μMJAG-6AorTMZupto24 hours.Total protein lysateswereanalyzedbyWesternblotting for total p53orbactin. (I)
UP-029 aHGG cells were cultured under normoxic conditions (21% O2) and exposed to 10 μM of each JAG agent up to 12 hours.
Expression of p21, PUMA, and Bax mRNA was measured; n¼ 3. Shown are fold change in each gene relative to GAPDH mRNA of
chemotherapy-treated versus mock-treated cells normalized to 1.0. (J) UP-029 aHGG cells were cultured under normoxic conditions
(21%O2) and exposed to 10mMof TMZ or 30 μMgemcitabine up to 12 hours. Cells were collected at the end of each incubation. RNA
was extracted and qRT-PCR for PUMA and BaxmRNA was analyzed. n¼ 3, error bars indicate ±SD.
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treatment (UP-029, 44.321% ± 6.254% and KNS42, 88.1%
±4.379%, respectively) was noted. The remaining JAG agents
showed only a modest increase in cell death up to 72 hours. As we
observed in our 2D studies, JAG-6Aetreated spheres displayed a
significantly increased total sum of dead cells (Figure 5E). Based on
these data, we concluded that JAG-6A retained efficacy in 3D HGG
models. In contrast to our 2D studies where CC-I instigated asignificant reduction in the viability of UP-029 cells, in UP-092 3D
spheroids, CC-I effectiveness was significantly attenuated. These data
raised the hypothesis that the reduced surface area of the spheroid or
the diffusion of CC-I through the cell mass was diminished. UP-029
aHGG showed a significant increase of PUMA and Bax transcription
post JAG-6A treatment of the spheroids and a significant increase in
Bax transcription post TMZ exposure (Figure 5F). Consistent with
Translational Oncology Vol. 12, No. 10, 2019 DIVERSet JAG Compounds in High-Grade Glioma Howarth et al. 1383our viability studies, CC-I exposure did not induce the transcription
of either PUMA or Bax in our 3D spheroids.
Our data revealed that JAG-6Adirected a clear anti-HGG response in
both 2Dand 3Dmodels independent of the environmental oxygenation
conditions. However, it remained elusive as to how JAG-6A could elicit
this response. To answer this question, we conducted molecular
modeling studies. We noted that, with the exception of JAG-79, each
JAG agent bound to human topoisomerase IIa. The predicted binding
location for JAG6A, CCI, and JAG32 was inside the topoisomerase IIa
cavity, where we hypothesized that they may function as an inhibitor
(Figure 5G). Etoposide (a known topoisomerase Iia) poison and
chemotherapeutic agent also bound in this cavity. Whereas the best
binding energies (kcal/mol1) for JAG6A,CCI, and JAG32were found
to be inside the same region of space within topoisomerase IIa
(Figure 5H), the JAG79 molecule was outside of this region. The
modeling profile and location for JAG-79 in part suggest a compelling
reason why the effectiveness of this compound was significantly worse
than all of the other JAG agents examined. We performed kDNA
decatenation assays to determine the ability of these compounds to
inhibit topoisomerase IIa enzyme activity. As we predicted, etoposide
potently inhibited topoisomerase IIa. Strikingly, we observed that
JAG6A, CC-I, and JAG32 inhibited topoisomerase IIa activity in a
dose-dependent manner. At concentrationsz50 mM,CC-Ieinhibited
topoisomerase IIa catalyzed kDNA decatenation, but noticeably, both
JAG6A and JAG32 inhibited topoisomerase IIa kDNA decatenation at
5 mM (Figure 5I). We note that JAG79 had no effect on topoisomerase
IIa kDNA decatenation, consistent with the predicted inability to bind
within the topoisomerase IIa cavity. These data indicated that the
anti-HGG effect mediated by these agents, in particular JAG6A, is by
the potent inhibition of topoisomerase IIa.Discussion
In both adult and pediatric patients, HGG treatment efficacy is
extremely limited due to widespread resistance to conventional
chemotherapeutics. Novel agents that are more potent than those
currently available (including TMZ and etoposide) are urgently
needed, in particular, agents that are less toxic to non-neoplastic cells.
Herewe have compared a number of novel anticancer agents to various
conventional frontline chemotherapeutics.We conducted this evaluation
using a range of classic and new patient-derived aHGG cell lines.
Furthermore, we included two pediatric HGG in vitro models. We
examined the anticancer effectiveness of each compound including the
level (and activation) ofHIF-1a and p53.Usingmolecular modeling and
enzymatic assays, we identified that topoisomerase IIa was the cellular
target of our novel agents and that the lead JAGcompound (JAG-6A)wasFigure 5. Novel aHGGmodels form spheroids. Adult/pediatric HGGs
of 5103 UP-029 aHGG or KNS42 pHGG cells were cultured under u
lines formeddense,highly viable spheroids. (B) SEMofeachspheroid
or KNS42 spheroidswere treatedwith TMZ (10mM) or JAGagents (3
live, and dead cells was conducted (seeMethods). (D) Percentage of
number) of dead cells (per spheroid/micron2) is presented as mean
adherence conditions at 21% O2 and then exposed to 10mM of T
collected at the end of each incubation. RNA was extracted, and p21
ANOVA was conducted, and P values are shown for each compariso
bindingcavityof topoisomerase IIa is shown inyellow.Topoisomerase
site. (H) Binding energy (kcal/mol1) for each JAGagent and etoposid
topoisomerase IIa cavity. (I) The JAG agent concentration-depen
decatenation.All experimentswerecarriedout according to instructio
of enzyme, 0.26mgofDNAsubstrate, and the indicated concentratio
Different topological forms exhibited different mobility as indicated.a potent inhibitor of this enzyme. Consistent with this inhibition,
JAG-6Adirected the strongest anti-HGG response, and this responsewas
not diminished when cells were cultured and then treated under hypoxic
(1% O2) conditions. Consistent with this efficacy under hypoxic
conditions, when adult or pediatric HGG lines were cultured in 3D
spheroids, JAG-6Amediated a potent anti-HGG response. Interestingly,
JAG-6Ahad a significantly lower EC50 compared toTMZwhenUP-029
or KNS42 3D spheroids were treated. JAG-6A exposure triggered a
significant induction of the p53-dependent target genes PUMA and Bax
with a concomitant increase in both proteins up to 24 hours.We did not
observe an increase of p21 transcription, consistent with the induction of
apoptosis we report and the known prosurvival role of p21 [43] [44,45].
Within our small adult cohort, all patients underwent the Stupp
protocol post biopsy surgery. Patients with biopsy lines that responded
poorly (or not at all) to JAG-6A (as well as TMZ) had a significantly
worse clinical outcome. UP-029 and SEBTA-025 showed a potent
response to JAG-6A (and TMZ). SEBTA-003 (with unmethylated
MGMT) was resistant to TMZ, although it was sensitive to JAG-6A,
highlighting a divergent mechanism of action (a topoisomerase Iia
inhibitor compared to aDNA alkylating agent). SEBTA-023was highly
resistant to conventional treatments and JAG-6A, likely in part to the
p53 status of thismodel, a finding consistent with reports demonstrating
that topoisomerase IIa inhibitors direct p53-dependent cell death
[46e48]. There are a number of processes that might modulate cancer
susceptibility to etoposide, including the level of topoisomerase II
expression (at the level of both transcription and translation), the DNA
binding of topoisomerase II, its activity following DNA binding, and
topoisomerase II posttranslational modifications. Mutations in the
Kelch-like ECH-associated protein 1 (KEAP1), the SWI/SNF complex (a
nucleosome remodeling complex), and the methyltransferase EZH2
influence topoisomerase II at a transcriptional level, modifying
susceptibility to topoisomerase poisons [49e52]. An extensive evalua-
tion of cell line sensitivity to etoposide highlighted that formany classical
high-grade glioma lines, their response were comparable to that of small
cell lung cancer and myeloma, both cancers that have traditionally been
treated with etoposide [35]. At present, there are a number of
investigations of topoisomerase poisons in combination with novel
delivery mechanisms. This includes pediatric brain tumors, where laser
interstitial thermal therapy is applied to disrupt the bloodebrain barrier
and enhance the delivery of this (and other) chemotherapeutic agents
(ClinicalTrials.govNCT02372409). Another glioma clinical trial is
investigating etoposide in combination with sodium thiosulfate in order
to determine if the addition of sodium thiosulfate can protect against
thrombocytopenia (low blood platelet count) noted post etoposide
administration (ClinicalTrials.gov-NCT00075387) [49].pheroids are sensitive to specific JAG anticancer agents. (A) A total
ltra-low adherent conditions. Twenty-four hours later, both in vitro
model; left panel scalebar: 50 μm, right panel scale bar. (C)UP-029
0 μM). Seventy-twohours posttreatment, triple staining for nuclear,
PI-positive (dead) cells are presented asmean± SD. (E) Sum (total
±SD. n¼ 6. (F) UP-029 adult GBM cells were cultured in ultra-low
MZ or 30 μM of each JAG agent up to 12 hours. Spheroids were
, PUMA, and Bax expression was analyzed. n¼ 3. For all, two-tailed
n. (G) Structure of each agent docked into topoisomerase IIa. The
isshownas thebrown-colored ribbonwith residueson thebinding
e. Note, themost energy-stable binding for JAG79 is outside of the
dent inhibition of human topoisomerase IIaemediated kDNA
ns from theTopogenkit (PortOrange, FL). Reactionscontained4U
nof each agent dissolved inDMSO (0.5% final concentration (v/v)).
Etoposide was included as a positive control.
1384 DIVERSet JAG Compounds in High-Grade Glioma Howarth et al. Translational Oncology Vol. 12, No. 10, 2019A personalized medicine approach to chemotherapy for brain
tumors can potentially enhance the efficacy of many treatments and
minimize unnecessary exposure to toxic agents that will not benefit the
patient. A critical caveat for the use of topoisomerase II inhibitors (such
as etoposide) relates to delivery effectiveness. Novel delivery techniques
may allow therapeutic intratumoral concentrations of topoisomerase II
inhibitors to be reached and minimize the systemic toxicity commonly
associated with these agents that so far has limited their effectiveness.
Our data presented here suggest that JAG-6A (a significantly smaller
molecular weight compound than etoposide) potently inhibits
topoisomerase II and remains effective independent of oxygenation
in both 2D and 3D models. Together, these data warrant further
investigation of JAG-6A for the treatment of high-grade gliomas.
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